The system is available for patients whose mitral valves are not working properly due to severe mitral annular calcification.

Abbott announced the FDA approved its transcatheter mitral valve replacement system for patients with severe mitral annular ...

Abbott said the Tendyne system addresses a significant unmet need in cardiac care, providing an option for patients ineligible for open heart surgery and whose valves cannot be successfully repaired ...

The FDA approved Abbott's Tendyne minimally invasive heart replacement for mitral valve disease that could disqualify ...

Abbott (NYSE: ABT) announced today that it received FDA approval for its Tendyne transcatheter mitral valve replacement (TMVR ...

The FDA gave the OK for the North Chicago-based medical device maker's Tendyne transcatheter mitral valve replacement.

For patients with severe MAC who are at high risk for open-heart surgery and whose mitral valve cannot be successfully repaired with the Abbott MitraClip™ device, Tendyne offers an alternative ...

An 11-year-old boy recently became the first person in the world to have an artificial heart valve replaced with a living ...

Abbott today announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendynetm transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease.

and resulted in shorter procedure times among patients undergoing transcatheter mitral valve replacement (TMVR). The data were presented today as late-breaking clinical research at the Society for ...

ABT wins FDA approval for its Tendyne TMVR system, offering a minimally invasive mitral valve replacement for high-risk patients with severe MAC.